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Proteoglycans in the central nervous system play integral roles as “traffic signals” for the direction of neurite outgrowth. This attribute of proteoglycans is a major factor in regeneration of
the injured central nervous system. In this review, the structures of proteoglycans and the evidence suggesting their involvement in the response following spinal cord injury are presented.
The review further describes the methods routinely used to determine the effect proteoglycans
have on neurite outgrowth. The effects of proteoglycans on neurite outgrowth are not completely understood as there is disagreement on what component of the molecule is interacting
with growing neurites and this ambiguity is chronicled in an historical context. Finally, the most
recent findings suggesting possible receptors, interactions, and sulfation patterns that may be
important in eliciting the effect of proteoglycans on neurite outgrowth are discussed. A greater
understanding of the proteoglycan-neurite interaction is necessary for successfully promoting
regeneration in the injured central nervous system.
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Introduction
Understanding the complex causes of disease and the inability of some tissues to repair following injury is a major priority in biomedical research. Historically, biomedical research
has followed a “cell-centric” model to explain and treat the
progression and pathophysiology of disease. Considering
the role of the extracellular matrix (ECM) in many diseases
is a relatively recent and departing approach. Though many
diseases are manifested by cellular insufficiencies, the environments in which the cells reside likely contribute and
initiate many pathophysiologic mechanisms. In this review,
we discuss one example of this interaction in a very unlikely
place, the central nervous system (CNS).
Until recently, the study of the CNS was predominated by
a “neuro-centric” model. The neuron is the “processor” cell
of the CNS. The neuron receives chemical signals, translates
them into electrical signals, and passes this message over to
the next neuron in a re-translated chemical signal. This process, known as synaptic signaling, is the work of the neuron.
However, the other three major cells of the CNS also play
important roles in proper functioning. Astrocytes, oligodendrocytes and microglia regulate the strength, response, rate,
and structure of neuronal signaling (Doretto et al., 2011;
Jourdain et al., 2007; Perea et al., 2009; Wake et al., 2009).
In addition, the astrocyte regulates the amount of chemical
signal reaching the neuron, the amount of neurotransmitter
stored for release, energy demands, and ionic homeostasis
(Belanger et al., 2011; Beller et al., 2011; Haydon and Carmi-

gnoto, 2006; Mack and Wolburg, 2013). Most importantly,
these three glial types contribute to the production of integral ECM components, specifically proteoglycans (Jander
and Stoll, 1996; Jones et al., 2002; Lander et al., 1998; Shioi et
al., 1995).
Our understanding of the ECM’s function in the CNS is
miniscule compared to our functional knowledge of the various CNS cell types themselves. Advances, which have gradually appeared over the past few decades, implicate the ECM
as a dynamic and important contributor to the development
of the CNS, as well as to the normal and aberrant function
of the CNS. A major impetus to investigate the role of the
ECM in the CNS was the observed interaction of proteoglycans with elongating neurons.

Proteoglycans are a complex component of the
extracellular matrix
Proteoglycans (PGs) are complex molecules comprised of a
core protein that is glycosylated and contains various types
of carbohydrate chains. PGs were originally isolated from
cartilage tissue in 1891. At this time, PGs’ sole biological
function was believed to be as a molecule to fill space and
supply structural support within the extracellular matrix
(ECM) (for review: Yanagishita, 1993). Contrast this assessment with the current view of the ECM’s role in the
progression of disease, which has more recently gained great
attention (Cox and Erler, 2011; Curinga et al., 2008; Lu et
343
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al., 2011; Snow, 2011). In all, the ECM plays an important
role in development, regulation of synapses, the progression
of neurodegenerative disease, and repair following injury
(Fawcett and Asher, 1999; Franco and Muller, 2011; Lukes et
al., 1999; Pyka et al., 2011). Of the many components of the
ECM, proteoglycans appear to be the major influencer in the
ECM’s role in CNS physiology (Fitch and Silver, 2008; Galtrey and Fawcett, 2007; Hartmann and Maurer, 2001).

depicted in Figure 2, PGs have different sizes, levels of glycosylation, and cellular localization. These different characteristics are plausible factors that determine the type of interaction PGs have with elongating neurites, which is a major
agenda of this review.

Proteoglycans
There are three major classes of PG including heparan sulfate
proteoglycans (HSPGs), chondroitin sulfate proteoglycans
(CSPGs), and keratan sulfate proteoglycans (KSPGs). Each
class of proteoglycan is classified by the type of carbohydrate
chain attached to the core protein. Of particular interest to
CNS physiology are the CSPGs and HSPGs, which play pivotal roles in repair and reorganization following CNS injury
(Carulli et al., 2005; Galtrey and Fawcett, 2007; Jones et al.,
2003).
CSPGs are currently the most widely discussed proteoglycan in the field of neuronal regeneration. In the late 1980s,
when initial discoveries were being made about CSPGs and/
or their carbohydrate side chains, and affects on axonal outgrowth (Carbonetto et al., 1983; Verna et al, 1989; Snow et al.,
1990 a and b), conference presentations about CPSGs, e.g., the
Society for Neuroscience annual meeting, consisted of only a
few abstracts on the topic, while in 2013, there were > 50 abstracts devoted to CSPGs alone, and a magnitude more devoted to the involvement of ECM components in outgrowth and
regeneration, as determined by titles alone (SfN Proceedings;
website; 2013). Clearly, there has been an explosion of interest
and pronounced scientific advancement made on this topic.

The inability for the spinal cord to regenerate is a major
reason for the long-term disabilities and high societal costs
spinal cord injuries bare. As most tissues have an innate ability to regenerate, the innate CNS regeneration response does
not enable full anatomical and functional recovery. As regeneration of neurons often occurs locally, in a process called
“sprouting”, the new neuronal connections made are often
insufficient in providing functional recovery, but can sometimes be further burdensome in the form of pathological
pain (Harris, 1999; Shortland et al., 1997; Zhang et al., 2004;
Zimmermann, 2001). This makes CNS injury a particularly
challenging injury to overcome. Greater understanding of
the physiological response following SCI reveals PGs to be
culpable in preventing the injured spinal cord from regenerating. As with many damaged tissues, following injury to the
spinal cord, a scar forms. This scar, commonly referred to as
the glial scar, is caused by a proliferation of reactive astrocytes and acts as a barrier that surrounds the damaged tissue.
The glial scar reduces the damaging secondary insults that
can follow injury to the CNS, such as cytotoxic, excitotoxic,
and oxidative insults (Beller et al., 2011; Rolls et al., 2009;
Sofroniew, 2005). However, the formation of this scar is also
responsible for inhibiting the regeneration of the injured
spinal cord (Bovolenta et al., 1992; Hu et al., 2010; Rudge
and Silver, 1990). Intriguingly, the formation of the glial scar
is closely associated with increased expression of CSPGs.
A variety of CSPGs are elevated both acutely and chronically following SCI and localized within the glial scar and
surrounding areas. Following SCI in the rat, neurocan, brevican, and versican expression was increased in the area surrounding the injury up to 2 months post-injury. In addition,
neurocan, tenascin-C, and NG2 were significantly increased
and reached peak levels 8 days post-injury, while expression
of other CSPGs, phosphacan and brevican, are increased and
reach peak levels 1 month post-injury in the rat. These increases in PG protein were localized to regions that contain
fibronectin scar tissue (Jones et al., 2003; Tang et al., 2003).
Furthermore, the expression of some CSPGs following spinal cord injury is closely associated with the areas adjacent
to the forward process of transected axons, appearing as a
stop sign to a regenerating neuron (Jones et al., 2002).
The increase of PG expression within the glial scar and the
inability for the injured spinal cord to grow beyond the glial
scar implicates a direct role of CSPGs in the inability for the
injured spinal cord to regenerate. In vitro experimentation
has demonstrated CSPGs ability to inhibit neurite outgrowth
and regeneration. For instance, PGs extracted from the epicenter of a rodent SCI inhibited neurite outgrowth from
various neuronal cell-types (McKeon et al., 1995). While,
versican and brevican (which are elevated following injury)

CSPGs
CSPGs are linked to carbohydrate chains containing
N-acetylgalactosamine (GalNAc) and glucuronic acid (GlcA)
(Hardingham and Fosang, 1992; Poole, 1986), and exist in
both cell membrane bound, excreted and ECM embedded
forms. The family of CSPGs is highly variable having multiple core proteins, differing number and length of associated
sugar chains, as well as a variety of differing sulfation patterns, which imbue diversity of function. The GlcA can be
sulfated in the 2-carbon position, referred to as CS-2. The
GalNAc sugar amine can be sulfated at either the 4- or 6position, or at both the 4- and 6- position (DeLuca et al.,
1973). These are referred to as CS-2, CS-4, CS-6, or CS-4,6
respectively (Figure 1A, B).
HSPGs
The HSPG family of PGs contain both cell membrane bound
and excreted forms. Major transmembrane bound HSPGs
are the syndecans and glypicans. Major components of the
ECM include perlecan, agrin, and collagen XVII. Heparan
sulfate chains are variably sulfated at either carbon 3 or 6 of
GlcNAc or oxygen 2 position of GlcA (Figure 1C, D).
Figure 2 is a schematic representation of the wide variety
of chondroitin and heparan sulfate proteoglycans. As also
344
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Chondroitin sulfate 2,4,6S
GalNAc
GlcNAc

GlcUA

GalNAc-4S

GlcNAc-3S

GalNAc-6S

GlcUA-2S

D

GlcNAc-6S

GalNAc-4S,6S

Heparan sulfate 2,6S

Figure 1 Structural components of chondroitin sulfate and heparan sulfate glycosaminoglycans.
Structural components of chondroitin sulfate and heparan sulfate glycosaminoglycans. (A) Chondroitin sulfate chains are comprised of repeating disaccharide units of N-acetylgalactosamine (GalNAc) and glucuronic acid. GalNAc is either not sulfated, or sulfated at the 4, 6 or both 4 and
6 carbon positions. (B) These chains are arranged by the formation of a 1,4-β-glycosidic linkage. (C) Heparan sulfated chains are comprised of
repeating disaccharide units of N-acetylglucosamine (GlcNAc) and glucuronic acid (GlcA). GlcNAc is either not sulfated, or sulfated at the 3 or 6
carbon position. GlcA may be sulfated at the 2 carbon position. (D) Like chondroitin sulfate these disaccharides are linked through a 1,4-β-glycosidic linkage. The chemical structures in Figure 1 were produced using Marvin Sketch Version 6.1.0, which was used under the ChemAxon Ltd. free
educational license.

345

Beller JA, et al. / Neural Regeneration Research. 2014;9(4):343-355.
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Aggrecan
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Neurocan
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Phosphacan
Neuroglycan-C
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Figure 2 Proteoglycans are proteins that vary in size, localization, and degree of post-translational modifications.
There are many different proteoglycans that vary in size and degree of glycosylation. In addition, the localization of these molecules varies depending on the type and tissue, as some are bound to the extracellular matrix through hyaluronan or collagen (top panel) or found in the membrane or
excreted into the extracellular space (bottom panel).
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were demonstrated to contribute to the growth inhibitory
activity of myelin, as treatment with β-xyloside (a PG synthesis inhibitor) greatly increased the growth permissiveness
of oligodendrocytes (producers of myelin) (Niederost et al.,
1999). In addition, CSPGs produced in reactive astrocytes,
like those that makeup the glial scar inhibit neurite outgrowth in vitro (Bovolenta et al., 1997; Canning et al., 1996).
The historical precedent for CSPGs ability to inhibit neurite
outgrowth is discussed, in detail, later in the review.
Further evidence for the role of CSPGs following SCI
comes from animal models of SCI. Treatments that have
directly targeted the CSPGs of the glial scar have been modestly effective at promoting growth across the injury site and
functional recovery in rodents. For instance, treatment of the
injured spinal cord with the bacterial enzyme chondroitinase
ABC (cABC), which removes the chondroitin sulfate chains
of CSPGs, can improve neuronal growth across the glial scar
and improve functional outcome (Bradbury and Carter,
2011; Bradbury et al., 2002; Garcia-Alias et al., 2009; Huang
et al., 2006; Massey et al., 2006; Tom et al., 2009). In addition, degradation of a specific CSPG core protein, aggrecan,
enhances functional recovery following SCI (Tauchi et al.,
2012; Snow, et al., unpublished data).
The connection between SCI, CSPGs, and failed regeneration is based on experimental observations. The increase
in PG expression in the glial scar, the ability for these PGs
to inhibit neurite outgrowth, and the inability for neurons
to grow across the glial scar suggests that there is a direct
interaction between PGs and an outgrowing/regenerating
neurite. Though this evidence implicates PGs as having a
profound effect on neurite outgrowth the exact mechanisms
responsible for these interactions are unknown. Therefore, it
is the goal of our review to explain where and how we got to
the current understanding of this interaction and where this
field of research is heading. As PGs’ role following SCI has
been, and continues to be, a major impetus for examining
the exact mechanisms by which PGs interact with outgrowing neurites, specifically, with the sensorimotor leading end
of the neurite, the neuronal growth cone (Beller et al., 2013;
Cajal, 1892; Letourneau et al., 1994). A deeper understanding of this interaction will yield new modes of therapy aimed
at improving neuroregeneration following SCI.

Traditional and novel methods to analyze PG
interactions with neuronal growth cones,
axons, and cell bodies
There are three major in vitro methods for analyzing the
interaction of PGs with outgrowing neurons, neurites andgrowth cones.
Soluble PG outgrowth models
The simplest and first method used to analyze the influence of PGs on neurite outgrowth was the introduction
of PGs in solution, i.e., delivering PGs in the media to attached, outgrowing neuronal cells. The advantage to this
method, still used, is that multiple concentrations of PGs
can be easily and quickly tested for their effect on neurite
outgrowth (Snow et al., 1996). The disadvantage to this

approach is the physiological relevance. For instance, in the
extracellular matrix, PGs are commonly physically attached
to hyaluronan and other ECM molecules and not simply
floating in the extracellular milieu (Frantz et al., 2010). This
may alter the observed effect of the PG on the outgrowing neurite, and it may allow for interactions with the PG,
that when coupled to the ECM, may not be possible. For
instance, when laminin, a growth permissive substrate for
neurons, and aggrecan, a growth inhibitory CSPG, are both
substratum adsorbed in vitro, the order of application of
these compounds effects the behavior of the neurons (Condic et al., 1999). In particular, when aggrecan was adsorbed
to the substrata in the presence of laminin in solution,
the aggrecan was more inhibitory than when the aggrecan
was bound either before or after adsorption of laminin to
the substratum. This suggests that an interaction between
laminin and aggrecan is essential for the inhibitory nature
of aggrecan. In addition, electrochemical and steric interactions between the PG molecules themselves may be altered
when not physically coupled to the ECM. These were early
“lessons learned” and have shaped the specifics of more
refined methods now in use. For example, to account for
these interactions, methods in which PGs are substratum
bound and presented directly to outgrowing neurites were,
and are, also still widely used.
The “stripe assay” (also “patterned assay” or “choice assay”)
The “stripe assay” is a widely used patterned outgrowth assay
developed to analyze the response of elongating neurites to
CSPGs in much the same way a developing or regenerating
neurite might encounter cells expressing CSPGs in vivo, e.g.,
the glial scar (Snow et al., 1990). The “stripe assay” uses an
alternating pattern of substratum-bound growth-permissive molecules, often laminin but also fibronectin, collagen,
NCAM, or others, and the experimental PG (Snow et al.,
1990; 2001). Commonly, neuronal explants or dissociated
cells, e.g., sensory dorsal root ganglion (DRG), are placed
alongside a substrate-bound PG stripe and the effect on
neurite outgrowth is determined in a variety of ways (i.e., inhibition of forward elongation by examining the number of
neurites turning versus crossing the stripe; growth cone morphology; growth cone retraction, etc.). For instance, when
the CS/KSPG, aggrecan, the V2 splice variant of versican,
and tenascin, were tested using the “stripe assay”, there was a
significant reduction in the number of neurites growing on
the stripes containing the PG (Krull et al., 1994; Schmalfeldt
et al., 2000; Snow et al., 1990; Treloar et al., 2009). In addition, this method is also extremely useful in examining other
effects than just total outgrowth. For example, the “stripe assay” was also used to measure the effect PGs have on calcium
signaling, rate of neurite elongation, and filipodia behavior
(Snow et al., 1994; 1996). Further, the method was also used
to develop semi-automated approaches to quantitatively
determine the relative level of inhibition of various PGs by
calculating an “inhibitory index” (Hynds and Snow, 2002).
More recently, the method was adapted to measure subtle
changes in growth cone morphology, filipodia behavior, and
growth cone velocity in response to structural variants of
the CSPG aggrecan (Beller et al., 2013). This highly useful
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and commonly employed method provides a means to examine the effect a steep change from a growth permissive to
a growth inhibitory substratum has on neuronal outgrowth.
This represents the pattern of CSPG an outgrowing neurite
may encounter when approaching the ECM presented by the
glial scar. Next we describe another type of patterned assay
that examines a gradient of PG expression, i.e., a less steep
presentation of PGs. This model represents a different way
the PGs expressed by glial scars or other key depositions of
ECM may present themselves to outgrowing neurites.
Gradient assays
Gradient assays facilitate the examination of the effect a
more gradual change in concentration of substrate-bound
PG and growth-permissive substrata have on neurite outgrowth. There are two major methods to examine PG
gradients, namely the “step-gradient” (Snow and Letourneau, 1992) and the “spot gradient” (Tom et al., 2004). The
“step-gradient” is a modified stripe assay with increasing
concentrations of PGs on each subsequent step of the gradient. The “spot-gradient” is a gradient formed by adhering a
spot of PG to the substratum (often laminin) and diffusion
of the PG around the initial spot forms a gradient. These
assays have been used to study the effects of an approaching growth cone interacting with increasing concentrations
of PG, the formation and behavior of dystrophic growth
cones, identifying PG receptors, and to model the effect PGs
have on neurite outgrowth following macrophage induced
axonal dieback (Busch et al., 2010; Shen et al., 2009; Snow
and Letourneau, 1992; Tom et al., 2004). Together these
substratum-bound methods used to analyze the PG-neurite
interaction successfully model various aspects of neuronal
interactions with the glial scar formed following injury, and
represent the predominate methods currently used to study
this interaction.

Tracing the history of proteoglycan
interactions with neuronal growth cones
The complex structure of PGs suggests a number of ways a
neuronal growth cone may interact with PG molecules (Figure 3). Though the field has grown since its beginnings (Carbonetto et al., 1983; Snow et al., 1990; Verna et al., 1989),
there is no consensus as to what part of the PG molecule is
the key player. There are at least two possible ways in which
a PG can physically interact with a neuronal growth cone in
a receptor-mediated fashion: interactions through the PG
core protein or through the associated GAG chains.
Interactions via the proteoglycan core proteins.
The hypothesis that the core protein is involved in neurite
inhibition arose from two studies conducted in 1991, in
which, CSPGs were extracted from rat brain and were enzymatically degraded to remove their attached GAG chains.
Intriguingly, these two studies revealed different effects of
the extracted PG purifications. Specifically, CSPGs extracted
from rat brain were adsorbed to the bottom of cell culture
plates as either intact CSPGs, the isolated CSPG core proteins (no GAG chains), or the isolated GAG chains. There
was an increase in neurite outgrowth of neocortical neurons
348

in response to the intact CSPGs and the intact CSPG core
proteins, but not with the purified GAG chains (Iijima et
al., 1991). This suggested that CSPG core proteins promote
neurite outgrowth, while GAG chains have no effect. In
contrast, CSPGs extracted from 10-day-old rat brain and
directly added to the media of PC12D cell cultures caused
an opposite effect. Intact CSPGs and CSPGs with the GAG
chains enzymatically removed inhibited neurite outgrowth.
In addition, the purified GAG from this extraction did not
inhibit neurite outgrowth, further suggesting that the core
proteins themselves were responsible for inhibition (Oohira
et al., 1991). Although the measured effects on neurite outgrowth of these two early experiments were different, neurite
outgrowth promotion in the first and inhibition in the latter,
they both suggested that PGs effect on neurite outgrowth
was dependent on the core protein.
Further experimentation analyzed specific PG core proteins and their effect on neurite outgrowth. In 1994, experimentation with purified NG2 further supported the role
of CSPG core proteins involvement in neurite inhibition.
Embryonic rat DRG neurons outgrowth was inhibited by
intact NG2 and was also inhibited after enzymatic removal
of CS chains by chondroitinase ABC, thus suggesting a direct
role of the NG2 core protein in neurite outgrowth inhibition
(Dou and Levine, 1994).
A repulsive and differentiation-promoting influence of the
phosphacan core protein was demonstrated by Maeda and
Noda (Maeda and Noda, 1996). In brief, cortical neurons exposed to purified phosphacan (intact and following chABC/
keratanase digestion) displayed less neurite outgrowth and
enhanced morphological differentiation. Similarly, brevican
bound to astrocyte cell surfaces through the C-terminal portion of the core protein, inhibited neurite outgrowth in vitro
in cerebellar granule cells independent of GAG chains (Yamada et al., 1997). In 1999, evidence suggesting that different neuronal types may respond differently to the same PG
was reported. The mouse homolog of phosphacan (DSD-1),
caused opposing effects on neurite outgrowth dependent on
the neuronal cell type, as the core protein inhibited neurite
outgrowth from DRG explants and did not affect outgrowth
of hippocampal neurons (Garwood et al., 1999). This important study not only strengthened the belief that core
proteins affect outgrowth, but also suggested the important
idea that different cell-types react differently to PGs. Further
studies of phosphacan and neurocan revealed that core proteins inhibited neurite outgrowth of retinal ganglion cells independent of chondroitinase digestion (Inatani et al., 2001).
In 2003, the outgrowth of peripheral and CNS-derived neurons in response to versican V2 was measured. Purified versican V2 core protein was inhibitory to neurite outgrowth, as
an undigested PG, following digestion with chondroitinase
ABC and removal of N- and O-linked oligosaccharides. This
versican V2 inhibited neurite outgrowth from both peripheral and CNS-derived neurons. Only digestion of the core protein itself abolished versican V2 mediated neurite outgrowth
inhibition (Schmalfeldt et al., 2000). More recently, PI3-K
activation was measured in response to neuroglycan-C and
a recombinant neuroglycan-C that lacked associated GAG
chains. Both the intact and recombinant neuroglycan-C ac-
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1980
Glycosaminoglycans inhibit neurite
outgrowth on fibronectin.
(Carbonetto et al., 1983)

Different glycosaminoglycans affect
neurite outgrowth differently.
(Verna et al., 1989)

1990

Core proteins are responsible for
proteoglycans effect on neurite
outgrowth.
(lijima et al., 1991; Oohira et al., 1991)

Keratan sulfate and chondroitin
sulfate are necessary for inhibitory
action of aggrecan.
(Snow et al., 1990)

Different core proteins have different
direct effects on neurite outgrowth.
(Dou et al., 1994; Madea et al., 1996;
Yamada et al., 1997)

Chondroitin sulfate is the
major inhibitory GAG.
(Snow et al., 1992; Friedlander et
al., 1994; Milev et al., 1994)

Depending on the neuronal cell-type
GAGs and core proteins have
differential effects.
(Garwood et al., 1999)

2000

2010

Spliceforms of core proteins differentially
effect neurite outgrowth.
(Schmalfeldt et al., 2000; Wu et al., 2004)

Different sulfation patterns of
chondroitin
sulfate are more or less inhibitory to
neurite outgrowth.
(Gilbert et al., 2005; Wang et al., 2008;
Karumbaiah et al., 2011)

PTPsigma respresents a receptor for
chondroitin sulfate and heparan sulfate.
(Shen et al., 2009; Coles et al., 2011)

Variations in core protein fragmentation, GAG
chain length and
amount differentially effect growth cone response.
(Beller et al., 2013)

High-throughput neurite outgrowth assay to determine
contributions of PG structure on neurite outgrowth.
(Beller et al., 2014)

Figure 3 Timeline of advancements in the understanding of the role proteoglycans play in neuronal outgrowth (Selective list; not intended to
be exhaustive).
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tivated the PI3-K pathway and promoted neurite outgrowth,
suggesting the core protein was involved in both (Nakanishi
et al., 2006). Based on this long list of results from a variety
of laboratories, it is clear that PG core proteins regulate neurite outgrowth, although the specific mechanisms and differences between results are not well understood.

Thus, both components of PGs have measureable effects
on neurite outgrowth. However, the mechanisms of each of
these regulatory effects are not well delineated and underlie
the basis of many lines of current research in the field (Beller
et al., 2013; Brown et al., 2012; Dickendesher et al., 2012;
Matsuo and Kimura-Yoshida, 2013; Yu et al., 2013).

Interactions via the glycosaminoglycan chains
The alternative, and to many, the leading hypothesis in the
field of PGs influence on neurite outgrowth is that there
are direct interactions between the elongating/regenerating
growth cone and the GAG chains of PGs. This hypothesis is
supported by many results that conflict with those discussed
above. For example, in 1982, the first evidence suggesting
the role of GAG chains in the control of neurite outgrowth
was reported, while experimenting with heparan sulfate.
Rat sympathetic neurons were placed onto matrix produced
by cultured bovine endothelial cells. The neurons extended
neurites in the absence of nerve growth factor. Only treatment with heparanase abolished this neurite extension in the
absence of NGF. This pivotal study led to the hypothesis that
PG GAG chains have a direct effect on neurite outgrowth
(Lander et al., 1982). In 1990, a pivotal study examining
the proteoglycan aggrecan (at the time known as KS/CSPG) was published. In this report, a novel, and now classic,
method for testing neurite outgrowth was presented (see
Ways to Measure Outgrowth). Using enzymatic digestion, it
was determined that KS and CS were essential for complete
inhibition (Snow et al., 1990). Following this study, in 1991,
a keratan sulfate proteoglycan extracted from developing
chick CNS inhibited neurite outgrowth in vitro and the inhibition of this PG was abolished with keratanase treatment
(Cole and McCabe, 1991). These three studies presented an
alternative hypothesis to that presented above, in particular,
that the GAG chains of PGs were responsible for imparting
either the growth promoting or inhibiting activity of PGs.
In 1994, the effect of neurocan and phosphacan on the
adhesion molecules N-CAM and Ng-CAM were described.
N-CAM and Ng-CAM are members of the cadherin family
and are integral mediators of neurite outgrowth, as cadherins act as substrates for neuronal adhesion. Neurocan and
phosphacan bind to N-CAM and Ng-CAM and inhibit neurite outgrowth and cell attachment. In addition, the binding
of neurocan and phosphacan to N-CAM and Ng-CAM was
significantly reduced following chondroitinase digestion, implicating the role of neurocan and phosphacan GAG chains
in the inhibition of neurite outgrowth and cell adhesion
(Friedlander et al., 1994; Milev et al., 1994). Further supporting the role of GAG chains in outgrowth determination,
in 1995, chemical inhibition of GAG formation by treating
astrocytes with beta-D-xylosides or sodium chlorate caused
a significant increase in neurite outgrowth in treated-astrocyte-conditioned media and on the treated-astrocytes themselves (Smith-Thomas et al., 1995). Additionally, in 1999,
NG2 produced by astrocytes with CS chains attached was
inhibitory to DRG neurons, while removal of NG2 CS chains
was growth permissive (Fidler et al., 1999). This suggests
that GAG formation is necessary for the inhibitory activity
of astrocytic PGs, like those found in the injured spinal cord.

New ways of thinking about the interaction
between PGs and neurite outgrowth
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HSPGs versus CSPGs: Go versus Stop
As reviewed above, there is a large amount of uncertainty
as to how PGs can elicit such a diverse spectrum of effects
on neurite outgrowth. There is no model that can predict
the effect a particular PG will have on an outgrowing neurite solely based on the type of core protein. However, when
comparing different GAG types a clearer delineation can
be drawn. In particular, the differences in the response to
HSPGs versus CSPGs.
As presented earlier, Lander et al.’s study conducted in
1982, showed that removal of heparan sulfate (HS) through
the action of heparanase abolishes the NGF-independent
outgrowth of sympathetic neurons, thus promoting neurite
outgrowth (Lander et al., 1982). In agreement, outgrowth of
spinal cord neurons, chick retinal neurons, motor neurons
and PC12 cells were also promoted by HSPGs (Campagna et
al., 1995; Hantaz-Ambroise et al., 1987; Kim et al., 2003). It is
widely suggested that the growth promoting effect of HSPGs
is due to their ability to bind and interact with growth factors. For instance, the transmembrane HSPG syndecan-3 is a
receptor for the glial cell-derived neurotrophic factor (GDNF)
and syndecan-3 binding to GDNF mediates cell spreading
and neurite outgrowth. In addition, knockout of syndecan-3
in mice caused a reduction in cortical GABAergic neurons, suggesting an important role in cortical development
(Bespalov et al., 2011). Similarly, the cell-surface-attached
HSPGs (i.e., glypican, perlecan, and agrin) are important
modulators of fibroblast growth factor signaling (Matsuo
and Kimura-Yoshida, 2013). HSPGs also interact with other neurite outgrowth regulating proteins. For instance, the
growth repulsive cue semaphorin-1a (for more discussion of
semaphorins; see Shen et al. in this issue) was ineffective in
motor neurons lacking the HSPG perlecan (Cho et al., 2012).
HSPGs also interact with Netrin-DCC (growth permissive),
and Robo-Slit (growth inhibitory) signaling to coordinate
the lateral positioning of dopaminergic axons leading into
the spinal cord by modulating the repulsive cues produced by
the Robo-Slit interaction (Kastenhuber et al., 2009). Indeed,
HSPGs appear to transduce a positive cue to outgrowing
neurites by promoting continued growth.
Unlike the HSPGs, CSPGs provide inhibitory cues to outgrowing neurites. For instance, brevican, aggrecan, NG2,
neurocan and phosphacan are inhibitory to DRG neurons,
cortical neurons, cerebellar granule neurons, and retinal
ganglion cells, respectively (Beller et al., 2013; Dou and
Levine, 1997; Inatani et al., 2001; Snow et al., 1990; Yamada
et al., 1997). However, there is conflicting data, which suggests that not all CSPGs interact with neurons to produce
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the same effect, and that this may be CSPG dependent or
neuronal cell-type dependent. For instance, DSD-1, the
mouse homolog of phosphacan, inhibited neurite outgrowth
from neonatal DRG neurons yet, it had no effect on embryonic hippocampal neurons (Garwood et al., 1999). Further,
different forms of the same CSPG may elicit different effects
in a class of neuron. For instance, the short isoform of phosphacan, a non-proteoglycan variant known as receptor protein tyrosine phosphatase-β (RPTPβ), promoted outgrowth
of neonatal cortical neurons (Garwood et al., 2003). In
addition, differences in splicing of a particular PG can affect
its effect on neurite outgrowth. For instance, the V1 isoform
of versican promoted neurite outgrowth of hippocampal
neurons, whilst the V2 isoform inhibited neurite outgrowth
of hippocampal neurons, retinal ganglion and DRG neurons
(Schmalfeldt et al., 2000; Wu et al., 2004). Other than neuronal cell-type, the form of the PG, or the splice variants, the
differential effect of particular CSPGs on neurite outgrowth
may be explained by the differences in the varied forms of
sulfation of the GAGs. This idea is one of the more recent
developments in the study of PGs, specifically, the effect of
different sulfation patterns on neurite outgrowth.
CSPG sulfation may affect signal
Investigating the effects that sulfation patterns and epitopes
have on neurite outgrowth is taking the forefront as the
most intricate understanding of the interaction of proteoglycans and neurite outgrowth (Habuchi et al., 2004; Holt
and Dickson, 2005). As explained earlier, there are four
major forms of CS, CS-2, CS-4, CS-6, and CS-4,6. Initial
experimentation examining the activity of these different
sulfation forms of GAGs studied purified preparations of
the CS chains alone. Though unlikely to perfectly mimic
the effect of CS attached to the core protein, these experiments did begin to unravel the role sulfation may play
in the differential response to CSPGs. These experiments
have demonstrated that depending on the neuronal celltype and predominant sulfation form of the PG, differential responses in neurite outgrowth were reported. When
CS-4 and CS-6 were added into the cell media, adhesion
of thalamic and hippocampal neurons to laminin and poly-l-lysine were reduced. However, only thalamic neuron
outgrowth was affected as CS-6 increased the amount of
outgrowth from thalamic neurons (Fernaud-Espinosa et
al., 1994). Similarly, in a different study, CS-4 was found
to be strongly inhibitory to cerebellar granule cells, while
CS-6 was not (Wang et al., 2008). These results seem to
suggest that one can predict a particular neuronal cell-type
response based on the interaction with CS specific sulfation
pattern. However, the association is not necessarily clear.
For instance, substrate bound CS-4,6 increased neurite
outgrowth of embryonic hippocampal neurons, while it
strongly inhibited DRG neurite outgrowth (Gilbert et al.,
2005). In partial agreement with the previous study, genetic
suppression of CS-4,6 in astrocytes through siRNA targeting of the sulfotransferases that produce the 4,6 sulfation
pattern, produced astrocytic proteoglycans with reduced

inhibition of neurite outgrowth in embryonic cortical neurons (Karumbaiah et al., 2011). Though developments are
expanding the role different sulfation patterns play in the
regulation of neurite outgrowth, the mechanism(s) and the
target(s) involved in this interaction are not known.

How do CSPGs regulate neurite outgrowth?
The regulation of neurite outgrowth is often envisioned as the
summation of negative and positive signals received by a neuron through receptor-mediated mechanisms. Though CSPGs
may act as a physical wall or barrier to extending neurites, it is
likely that CSPGs interact with an outgrowing neurite either
directly or indirectly with receptors located on the neuron.
Do PGs interact with the neuronal growth cone, axon, or
cell body?
Anatomically, the ECM surrounds all parts of cells including the growth cone, axon and cell body. Less clear is what
part or parts of a neuron are interacting with the PGs in
the ECM. Immunocytochemical and immuno-electron microscopic analysis of the distribution of phosphacan in the
olfactory nerve displayed a widespread distribution of the
PG on both the surfaces of neuronal cell bodies and neurites
(Nishizuka et al., 1996). In the CNS, neuronal cell bodies are
commonly surrounded by structures known as perineuronal
nets (PNN), which are enriched in proteoglycans (Celio and
Blumcke, 1994). In addition, these PNNs regulate synaptic
plasticity and synapse formation, by both interacting with
the cell body and neurites growing towards the surrounded
cell body (Pizzorusso et al., 2002; Wang and Fawcett, 2012).
Work conducted by our group previously demonstrated that
contact with CSPGs through either the cell body or growth
cone caused a significant increase in intracellular [Ca2+]
(Snow et al., 1994). Neuronal cell bodies in contact with
CSPGs located in Schwann cell membranes extend neurites
that are inhibited by contact with CSPG, however when the
Schwann cell membrane CSPGs are digested with chondroitinase, neuronal cell bodies in contact with these Schwann
cells extend neurites that are no longer inhibited by contact
with CSPGs (Castro and Kuffler, 2006). Likewise, postnatal
cerebellar granule cell bodies and neurites are both repulsed
through contact with CSPGs (Kaneko et al., 2007). It is not
clear at what locale the CSPGs are eliciting their effect.
Work in our group has focused on the rapid changes occurring following growth cone contact with CSPGs. Following growth cone contact with CSPG, there are rapid changes
in filipodia number, length, growth cone width, growth cone
length, and growth cone velocity (Beller et al., 2013). In addition, the majority of studies are focused on the interaction
of the neuronal growth cone’s contact with CSPGs, though
CSPG contact with the neuronal cell body also affects the
interaction of the neuronal growth cone with CSPG. For instance, neurons have the ability to“adapt” to the presence of
CSPGs contacting the cell bodies through the upregulation
of integrins and are no longer inhibited by CSPGs (Condic et
al., 1999; Lemons et al., 2005). It is clear that both the neuronal cell body and growth cone interact with CSPGs. However,
the similarities and differences in the neuronal response and
their dependence on where the CSPG is contacted is unclear.
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PGs as receptor “shuttles”
PGs may interact with an outgrowing neurite by acting as
a ligand “shuttle” and present a bound ligand to a recipient
receptor. For instance, the syndecans are a class of HSPG,
which play a key role in growth factor signaling sensitivity.
Through the interaction with the 2-O-sulfated iduronic
acid units of the HS on syndecan, many growth factors are
able to bind. Once bound to the HS, the growth factor is
presented and bound to its respective receptor. Signaling
pathways dependent upon syndecan binding include the
GDNF, FGF, Wnt, VEGF, and HGF pathways (Chen et al.,
2013; Chernousov and Carey, 1993; Tkachenko et al., 2005).
In particular, removal of N-syndecan HS chains reduced
neurite outgrowth in vitro and ex vivo in response to growth
factor stimulation, thus suggesting a growth-permissive
role of N-syndecan binding (Kinnunen et al., 1996). N-syndecan is implicated to signal through a Src kinase signaling
pathway, contribute to the development of axon tracts, and
the process of hippocampal long-term potentiation, all requiring neurite outgrowth (Kinnunen et al., 1998; Lauri et
al., 1999). Syndecans represent a way a PG may affect neurite outgrowth as a receptor or “shuttle” for growth factors.
However, there is also evidence of PGs as a ligand, binding to
cell-surface receptors.
PGs as ligands
Protein tyrosine phosphatase sigma (PTPσ) was recently discovered to be a receptor for CSPGs. This represents
an important step in understanding the manner in which,
CSPGs inhibit neurite outgrowth. Through a series of elaborate experimentation, PTPσ bound specifically to the CS
chains of CSPGs, and inhibited neurite outgrowth (Shen et
al., 2009). Further, HSPGs also bound to the PTPσ receptor
and acted as a switch between growth-promotion and inhibition. As binding to CSPG reduced neurite outgrowth, while
binding to HSPG increased neurite outgrowth (Coles et al.,
2011). PTPσ is not the only CSPG receptor as two members
of the Nogo receptor family are also CSPG receptors. NgR1
and NgR3 knockout mice have reduced CS binding and an
enhanced ability for axonal regeneration following optic
nerve crush, and reduced outgrowth inhibition in neurons
cultured on CSPG (Dickendesher et al., 2012). Initial steps
at elucidating the pathways these receptors signal through is
underway. Global analysis of the neuronal phosphoproteome
in response to CSPGs identified a number of proteins whose
phosphorylation state is regulated by CSPGs. The majority of
these proteins are found in important cellular pathways that
regulate cell morphology, nervous system development, and
RNA post-transcriptional modifications (Yu et al., 2013).
Knowledge of PGs role in the CNS has evolved overtime
from the discovery that PGs produced by cultured endothelial cells improve neurite outgrowth (Lander et al., 1982), to
the conclusion that both the PG core protein and GAG chain
affect neurite outgrowth in a neuron cell-type specific manner (Beller et al., 2013; Nakanishi et al., 2006; Snow et al.,
1990). The added knowledge on how PGs interact with outgrowing neurites allows for the continuing acceleration of
knowledge, as the role of PGs as receptor and ligand opens
up a new field of mechanistic and pharmacological research
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(Beller et al., in press; Dickendesher et al., 2012; Shen et al.,
2009; Tkachenko et al., 2005).

Future directions
Though the 30+ years of research into the role of PGs in the
regulation of neurite outgrowth has not led to a consensus
on the way they interact with an outgrowing neurite, many
tools and ideas integral to cracking the PG code have been
revealed. For instance, the recent discovery that PTPσ, NgR1
and NgR3 are CSPG receptors opens the path to a new field
of pharmacology. Now that CSPG targets are identified,
pharmacological analysis of the varying post-translational
modifications can be conducted. The binding affinities of
these substrates to the receptors can be compared to their
effect on neurite outgrowth and the relationship between
structure and function can be understood. In addition,
development of a high throughput method to analyze a large
number of proteoglycans on different neuronal cell types
will enhance our ability to determine neuronal specificity
and their response to PGs. For instance, through a series of
elaborate experimentation, a synthetic GAG containing only
CS-4,6 was found to bind with high affinity to the PTPσ
receptor and inhibited neurite outgrowth of dissociated and
intact DRG neurons. In addition, masking of this epitope
through a specific monoclonal antibody against CS-4,6 promoted neuroregeneration through the CSPG-rich glial scar
(Brown et al., 2012).
Our laboratory is currently producing CSPGs that have
defined sulfation patterns. Through reverse transcriptase
PCR we determined that HEK293T cells expressed all the
carbohydrate sulfotransferases that produce each of the
CSPG sulfation patterns, specifically CS-2, CS-4, CS-6, and
CS-4,6. By producing stable transfectants of these HEK293T
cells with shRNA directed towards specific CHSTs, we are
producing CSPGs that lack one of the specific sulfation patterns. This allows us to determine the contribution of each
of these sulfation patterns on neurite outgrowth. This will
require a large number of outgrowth assays. Therefore, our
laboratory has developed a high-throughput assay (Beller
et al., in press). This assay will allow the analysis of a large
number of proteoglycans and neuronal cell-types, in order
to determine the contribution of each sulfation pattern, proteoglycan core protein, and post-translational modification.
Results from these studies may lead to the development of
novel pharmacological approaches to enhance regeneration
of the injured spinal cord.

Conclusion
The complexity of both PG structure and the process of neuronal outgrowth makes deciphering the interaction between
PG and neurite an arduous task. Due to the high variability
in PG composition, the limitations in the models available
for assessing PG effect, the multiple ways PGs and neurites
are capable of interacting; a full understanding of the mechanism(s) at play are likely far off. However, it is clear that
PGs play an important role in the process of neurite outgrowth and contribute to the inability of the injured spinal
cord to regenerate. With continued persistence, a clearer pic-
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ture of the PG neurite interaction may lead to the ability to
not only regenerate, but also rewire, the injured spinal cord
and brain.
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